Patrys Ltd (ASX:PAB) will present new data from preclinical studies assessing PAT-DX1 in animal models of anti-neutrophil cytoplasmic antibody (ANCA) vasculitis, a type of auto-immune disease, at the 21st International Vasculitis Workshop in Barcelona next month.
Dr Kim O’Sullivan from Monash University in Melbourne will conduct the oral presentation, to be held during the plenary session on April 8, 2024, at 9:30am (CET time).
The presentation will examine pre-clinical studies that demonstrate the potential to improve the underlying processes associated with auto-immune diseases like ANCA.
New therapeutic opportunities
“Our collaboration with Dr Kim O’Sullivan at Monash University has continued to identify new properties for our deoxymabs that may open up new therapeutic opportunities,” Patrys CEO and managing director Dr James Campbell said.
“The recent studies, which will be presented at the 21st International Vasculitis Workshop in Barcelona to a knowledgeable and respected audience of industry peers, have indicated that deoxymabs may have a potential role in the treatment of various inflammatory diseases, and in particular certain types of vasculitis.
“As GMP manufacturing for PAT-DX1 remains on track to commence in the current quarter, it is exciting to identify additional therapeutic opportunities for our deoxymab platform with promising future partnering and licensing opportunities for Patrys.”
ANCA vasculitis or AAV is an autoimmune disease characterized by the pathological accumulation of activated neutrophils and neutrophil extracellular traps (NETs) within small blood vessels.
As current therapies render patients at high risk of serious infections, there is an unmet need for therapies without serious side effects.